📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. (2024)

First Author: Rosier M

Attributed to: Mass spectrometry underpinning synthetic biology, industrial biotechnology and world class bioscience funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/cancers17010081

PubMed Identifier: 39796712

Publication URI: http://europepmc.org/abstract/MED/39796712

Type: Journal Article/Review

Volume: 17

Parent Publication: Cancers

Issue: 1

ISSN: 2072-6694